

COVID19-RP PATIENT RESULTS

genetic molecular testing

PATIENT INFORMATION:

Smith, John

Sex: F
PID: 0015017
Age: 43
DOB: 10/11/1971
SSN: 000-00-0000

PHYSICIAN INFORMATION:

James Jones, MD

Medical Center
12 Old Street Road
Atlanta, Georgia 30301

CASE INFORMATION:

CASE: COVID19-RP-1000
Procedure Date: 08/01/2020
Received Date: 08/01/2020
Report Date: 08/01/2020

TEST RESULTS:

DETECTED

SARS-CoV-2

POSITIVE

- Adenovirus - *not detected*
- Coronavirus 229E - *not detected*
- Coronavirus HKU1 - *not detected*
- Coronavirus NL63 - *not detected*
- Coronavirus OC43 - *not detected*
- Human rhinovirus/enterovirus - *not detected*
- Human metapneumovirus - *not detected*
- Influenza A (subtype) H3 - *not detected*
- Influenza A (subtype) H1 - *not detected*
- Influenza A (subtype) H1-2009 - *not detected*
- Influenza A - *not detected*
- Influenza B - *not detected*
- Parainfluenza virus 1 - *not detected*
- Parainfluenza virus 2 - *not detected*
- Parainfluenza virus 3 - *not detected*
- Parainfluenza virus 4 - *not detected*
- Respiratory syncytial virus - *not detected*
- Bordetella parapertussis (IS1001) - *not detected*
- Bordetella pertussis (ptxP) - *not detected*
- Chlamydia pneumoniae - *not detected*
- Mycoplasma pneumoniae - *not detected*

97.1% Sensitivity, 99.3% Specificity

Specimen Source: Nasopharyngeal Swab

Methodology: Polymerase Chain Reaction
(Real Time PCR)

Interpretation: A positive test result for COVID-19 indicates that RNA from SARS-CoV-2 was detected, and the patient is infected with the virus and presumed to be contagious.

Significance: Laboratory test results should always be considered in the context of clinical observation and epidemiological data in making a final diagnosis and patient management decisions. Patient management should follow current CDC guidelines.

RECOMMENDATION:

Patient management should follow current CDC guidelines.

These tests have been authorized by the FDA under an EUA for use by authorized laboratories and have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. These tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act 21, U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

CPT:
Alpha Numeric Code: 02020U



Pathologist Electronic Signature
Armando Moncada Jr. M.D. FCAP